Saol Therapeutics’ mission is to have a measurable impact on the health and wellbeing of underserved patient populations. To that end, Saol is aggressively seeking out and developing new therapeutic options to support clinicians around the world – and most importantly – the patients they serve.
Our growing pipeline consists of four programs for CNS conditions and rare diseases. These programs span the development spectrum, from the preclinical phase in movement disorders to a Phase III asset targeting a first in class therapy where no options currently exist. In anticipation of multiple FDA approvals over the next three years, Saol continues to rapidly grow its organization, accelerating product development to enhance the treatment options for underserved patients.
Additionally, Saol is interested in partnering with others who are looking to accelerate their growth by leveraging the talent and capability of our highly experienced and entrepreneurial organization.
To learn more about partnering with Saol, please visit our Business Development page.